The problems of executive compensation at big financial companies like Merrill Lynch (NYSE: MER) and Citigroup (NYSE: C) are obvious. Executives who led their companies into massive losses on risky bets walked away with huge parting gifts, even as shareholders nursed billions in losses. Congress held hearings and financial journalists everywhere cried foul. But corporate governance helps people who help themselves and, for whatever reason, most shareholders have made the inexplicable decision that they don't even want an advisory vote on executive pay.
The Wall Street Journal reports (subscription required) that "At Citigroup Inc., J.P. Morgan Chase & Co., Merrill Lynch & Co. and Morgan Stanley, proposals that would let investors weigh in every year with a nonbinding vote on compensation got an average of just 37% of shareholder votes, according to the latest tallies. Similar proposals in last year's proxy statements for the same companies got 43% support."
How is that even possible? When the problem of pay gone wild is so obvious that even laissez-faire capitalists are saying something is screwed up, why would shareholders reject an opportunity to have their nonbinding voices heard? It just doesn't make any sense at all.
Part of the problem may be that individual investors aren't voting. But I also wonder whether there's some home cooking going on. Are the large institutional shareholders that control the bulk of these companies voting to keep the executive pay gravy train flowing because they have a personal stake in it?
If so, they should remember that their fiduciary duty lies with the investors for whom they own the shares. If regulators want to make themselves useful, they should take a look at this possible conflict of interest.
Last updated: February 13, 2012: 12:56 PM
Hot Stocks
DailyFinance Headlines
- Is It Already 'The End' for E-Book Readers?
- Retail Stocks Are for Suckers: Why Their Rally Won't Last
- Suddenly, Amazon Doesn't Love Its Moms Anymore
- How State Taxes Put a Bigger Pinch on the Poor
- 4 Money-Etiquette Questions Answered
Benzinga Headlines
- Airlines the Latest to Suffer Euro Crisis Blues
- Internet-Hungry Consumers Force Vodafone to Consider a C&W Offer
- Seven Japanese Stocks Up More Than 10% Year to Date
- Does the 2012 Election Really Matter for the Economy?
- Michigan Consumer Sentiment Index Drops
TheFlyOnTheWall.com Headlines
- On The Fly: Mid-Day Wrap
- Japan Airlines to invest Y500B in new planes, related spending, Nikkei reports
- Stocks with call strike movement; ZNGA BIDU
- NYSE market internals summary
- NASDAQ market internals summary
BioHealth Investor Headlines
- Can Human Genome Really Double Its Stock Price? (HGSI)
- Alimera Implosion Analysis, What Is Next (ALIM, PSDV)
- Implosion Analysis For Targacept… What Lies Ahead? (TRGT, AZN)
- Rare Analyst Calls With Huge Upside in Vical and VIVUS (VICL, VVUS, BMY)
- Top Biotechs With Upside Ahead of Earnings (GILD, AMLN, ARIA, INCY, JAZZ, DNDN, HGSI, ILMN, AMGN, CELG, BIIB, BMRN, LIFE, REGN, AMLN, CBST, ONXX, THRX, VPHM)
WalletPop Headlines
- Is It Already 'The End' for E-Book Readers?
- Retail Stocks Are for Suckers: Why Their Rally Won't Last
- Suddenly, Amazon Doesn't Love Its Moms Anymore
- How State Taxes Put a Bigger Pinch on the Poor
- 4 Money-Etiquette Questions Answered
My Portfolios
Track your stocks here!
Find out why more people track their portfolios on AOL Money & Finance then anywhere else.
BloggingStocks Partners
More from AOL Money & Finance
- Business News
- Stock Screener
- Stock Quotes
- Stock Charts
- Banking
- Identity Theft
- DJIA
- Debt Management
- Loans
- Auto Loan
- Mortgages
- Taxes
- Retirement
- Insurance
- Small Business
- Earnings
- Tech News
- Tax Forms
- Tax Deductions
- Tax Credit
- Tax Audit
- Tax Advice
- Stock Ticker
- Stock Brokers
- Resume Builder
- Pig Flu
- Online Tax Filing
- Madoff
- Investing For Retirement
- Income Tax
- Historical Stock Prices
- GOOG
- ETF Investing
- Deals
- DailyFinance
- Crude Oil Prices
- Credit Score Calculator
- Common Tax Filing Mistakes
- AMT
BioHealth Investor Headlines
- Can Human Genome Really Double Its Stock Price? (HGSI)
- Alimera Implosion Analysis, What Is Next (ALIM, PSDV)
- Implosion Analysis For Targacept… What Lies Ahead? (TRGT, AZN)
- Rare Analyst Calls With Huge Upside in Vical and VIVUS (VICL, VVUS, BMY)
- Top Biotechs With Upside Ahead of Earnings (GILD, AMLN, ARIA, INCY, JAZZ, DNDN, HGSI, ILMN, AMGN, CELG, BIIB, BMRN, LIFE, REGN, AMLN, CBST, ONXX, THRX, VPHM)
5-Hour Energy: A Success Equal Parts Caffeine, Chemistry and…
How State Taxes Put a Bigger Pinch on the Poor


Reader Comments (Page 1 of 1)
5-22-2008 @ 4:45PM
william lindblad said...
This was not just the big players, it includes all that were operating with a "more you write-the more you make" concept. That, coupled with oodles of cheap money gave us the present situation. The full extent of the write downs have yet to be realized and made public. The current UBS deep discount sale to Blackstone also has UBS loaning the buyer a large chunk of the purchase money. This smells more like accounting manipulation than a sale as there is little guarantee that Blackstone may have to due some further write down if the market continues to slide. This move seems to be more a "slight of hand" in which UBS removes these bad assets from their books and transfers them elsewhere. Swiss banking at it's finest.
We have yet to hear from the small to medium sized U.S. commercial banks and it is reasonable to assume there is a lot of red ink in this area also. Congress can hold all the hearings that they want but there is nothing that can be done about greed short of stringent regulation. Congress could give the shareholders greater authority but you cannot regulate human nature. Capitalism has it's bad points, but so does the Marxist theory. Neither can cope with greed and corruption, just as the Chinese how they are doing?